EE9400183A - Inimese immuunpuudulikkuse viiruse vaktsiin ja kasutamine - Google Patents

Inimese immuunpuudulikkuse viiruse vaktsiin ja kasutamine

Info

Publication number
EE9400183A
EE9400183A EE9400183A EE9400183A EE9400183A EE 9400183 A EE9400183 A EE 9400183A EE 9400183 A EE9400183 A EE 9400183A EE 9400183 A EE9400183 A EE 9400183A EE 9400183 A EE9400183 A EE 9400183A
Authority
EE
Estonia
Prior art keywords
vaccine
immunodeficiency virus
human immunodeficiency
human
virus
Prior art date
Application number
EE9400183A
Other languages
English (en)
Inventor
E. Smith Gale
Volvovitz Franklin
Original Assignee
Microgenesys, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microgenesys, Inc. filed Critical Microgenesys, Inc.
Publication of EE9400183A publication Critical patent/EE9400183A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EE9400183A 1991-06-11 1994-09-21 Inimese immuunpuudulikkuse viiruse vaktsiin ja kasutamine EE9400183A (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71415291A 1991-06-11 1991-06-11

Publications (1)

Publication Number Publication Date
EE9400183A true EE9400183A (et) 1995-12-15

Family

ID=24868938

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400183A EE9400183A (et) 1991-06-11 1994-09-21 Inimese immuunpuudulikkuse viiruse vaktsiin ja kasutamine

Country Status (18)

Country Link
EP (1) EP0542998A1 (et)
JP (1) JPH06501851A (et)
CN (1) CN1068266A (et)
AU (2) AU2193192A (et)
BG (1) BG97519A (et)
CA (1) CA2087732A1 (et)
EE (1) EE9400183A (et)
FI (1) FI930577A (et)
HU (1) HUT68355A (et)
IE (1) IE921875A1 (et)
IL (1) IL102092A (et)
LT (1) LT3365B (et)
MX (1) MX9202781A (et)
PL (1) PL297849A1 (et)
PT (1) PT100584A (et)
SK (1) SK18993A3 (et)
WO (1) WO1992022654A1 (et)
ZA (1) ZA924150B (et)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40786E1 (en) * 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
WO1995017515A1 (en) 1993-12-23 1995-06-29 University Technologies International Inc. Methods of expressing proteins in insect cells and methods of killing insects
AU723537B2 (en) 1995-06-07 2000-08-31 Trimeris Inc. The treatment of HIV and other viral infections using combinatorial therapy
US6395541B1 (en) 1996-05-23 2002-05-28 The Rockefeller University Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
US6319504B1 (en) 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6077662A (en) * 1996-11-27 2000-06-20 Emory University Virus-like particles, methods and immunogenic compositions
US6214540B1 (en) 1997-03-26 2001-04-10 University Of Maryland Biotechnology Institute Chemokines that inhibit immunodeficiency virus infection and methods based thereon
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US6548631B1 (en) 1997-09-16 2003-04-15 BIOMéRIEUX, INC. Macrophage derived chemokine (MDC) as an anti-viral agent for the treatment and prevention of lentivirus infection
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
US6623741B1 (en) 2000-02-29 2003-09-23 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
AUPS065002A0 (en) 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
EP1578766B1 (en) * 2002-12-03 2013-02-13 University of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
EP2270511A3 (en) 2003-10-24 2011-08-24 Immunaid Pty Ltd Method of therapy
PA8809601A1 (es) 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
ES2548508T3 (es) 2009-05-27 2015-10-19 Biotempus Limited Métodos de tratamiento de enfermedades
KR101911229B1 (ko) 2011-08-19 2018-10-24 임모탈 스피릿 리미티드 항체 및 항체 함유 조성물
CN102961760B (zh) * 2011-09-01 2017-07-18 常州文松生物技术有限公司 重叠肽作为制备皮肤试验和检测特异性细胞免疫的试剂及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1

Also Published As

Publication number Publication date
LT3365B (en) 1995-07-25
LTIP335A (en) 1995-01-31
ZA924150B (en) 1993-02-24
HU9300686D0 (en) 1993-06-28
SK18993A3 (en) 1993-10-06
EP0542998A1 (en) 1993-05-26
IE921875A1 (en) 1992-12-16
HUT68355A (en) 1995-06-28
FI930577A0 (fi) 1993-02-10
AU4028895A (en) 1996-02-22
PL297849A1 (en) 1994-01-24
FI930577A (fi) 1993-03-24
IL102092A (en) 1996-11-14
MX9202781A (es) 1993-04-01
PT100584A (pt) 1993-07-30
WO1992022654A1 (en) 1992-12-23
JPH06501851A (ja) 1994-03-03
CN1068266A (zh) 1993-01-27
AU2193192A (en) 1993-01-12
BG97519A (bg) 1994-03-24
CA2087732A1 (en) 1992-12-12
IL102092A0 (en) 1993-01-14

Similar Documents

Publication Publication Date Title
EE9400183A (et) Inimese immuunpuudulikkuse viiruse vaktsiin ja kasutamine
CY2007030I2 (el) Εμβολιο εναντια στον ανθρωπινο ϊο θηλωματος (τυπος 18)
NO921012D0 (no) Farmasoeytiske preparater og deres anvendelse
BR9206131A (pt) Hepatite C: diagnóstico e vacinas
EE03025B1 (et) Immunomoduleeriva toimega N,N'-diatsetüültsüstiini orgaanilised soolad, nende valmistamine ja kasutamine
NO994639L (no) Antimikrobiell forebyggelse og behandling av humant immundeficiensvirus og andre infektiöse sykdommer
EE9800382A (et) Lihtherpese viiruse ja teiste nakkushaiguste antimikroobne ravimenetlus
ES1005721Y (es) Sillo plagable con dos o mas posiciones de empleo
KR870700638A (ko) 임균의 주로 철-조절된 단백질과 이의 백신으로서의 용도
DK0589086T3 (da) Tandlæge-patientstol
IL99851A0 (en) Muramyldipeptide derivatives and influenza vaccine containing them
FI945427A0 (fi) Dynemisiinianalogien enantiomeerit, niiden valmistus ja käyttö
KR930702527A (ko) gp160의 유도체 및 보조약을 함유하는 gp160 또는 그의 유도체를 기재로하는 백신
FI944561A0 (fi) HIV:tä neutraloivia monoklonaalisia yhdistelmähumaanivasta-aineita HIV-infektion ehkäisemiseksi ja hoitamiseksi
DK1087014T3 (da) Svinepestvirusvaccine og -diagnostik
DE69032787D1 (de) Mutantes pseudorabiesvirus und dasselbe enthaltende vakzine
DK720588D0 (da) Forbindelser til anvendelse ved behandling eller forebyggelse af human-immundefektvirus-(hiv)-infektion, og farmaceutiske praeparater indeholdende samme
IT1239064B (it) Uso terapeutico del dipiridamolo
FI961869A (fi) Rokotteen suunnittelu ja valmistus
IL102815A0 (en) Pharmaceutical compositions and method for the treatment of infection caused by the human immunodeficiency virus
ITMI920261V0 (it) Vaporizzatore per scopi medicali e cosmetici
DK299889D0 (da) Kloning og ekspression af human vaevsfaktor
EP0541089A3 (en) Cdna of human hepatitis c virus, its clone and use thereof
DK630089D0 (da) Anvendelse af aryloxyalkanoler og estere deraf til fremstilling af farmaceutika til behandling af retrovirusinfektioner
FI980391A0 (fi) Polyhydroksisyklopentaanin johdannaiset, niiden valmistus ja terapeuttinen käyttö